Vaccines against ‘the other’ Ebolavirus species

References

• Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ. 1978;56(2):247–270.
   PubMed Web of Science ®Google Scholar
• Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56(2):271–293.
   PubMed Web of Science ®Google Scholar
• Ellis DS, Bowen ET, Simpson DI, et al. Ebola virus: a comparison, at ultrastructural level, of the behaviour of the Sudan and Zaire strains in monkeys. Br J Exp Pathol. 1978 Dec;59(6):584–593.
   PubMedGoogle Scholar
• Lupton HW, Lambert RD, Bumgardner DL, et al. Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet. 1980 [Dec 13];2(8207):1294–1295.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Pushko P, Anderson K, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002 May;8(5):503–507.
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000 [Nov 30];408(6812):605–609.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Strong JE, Feldmann H. Considerations in the use of nonhuman primate models of ebola virus and marburg virus infection. J Infect Dis. 2015 [Oct 1];212 Suppl 2:S91–7.
   PubMed Web of Science ®Google Scholar
• Jansen HJ, Breeveld FJ, Stijnis C, et al. Biological warfare, bioterrorism, and biocrime. Clin Microbiol Infec. 2014 Jun;20(6):488–496.
   PubMed Web of Science ®Google Scholar
• Kuhn JH, Dodd LE, Wahl-Jensen V, et al. Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror. 2011 Dec;9(4):361–371.
   PubMedGoogle Scholar
• De La Vega MA, Stein D, Kobinger GP. Ebolavirus evolution: past and present. PLoS Pathog. 2015 Nov;11(11):e1005221.
   PubMed Web of Science ®Google Scholar
• Anthony SM, Bradfute SB. Filoviruses: one of these things is (not) like the other. Viruses. 2015 Oct;7(10):5172–5190.
   PubMed Web of Science ®Google Scholar
• Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 2014 [Oct 9];371(15):1418–1425.
   PubMed Web of Science ®Google Scholar
• Alexander KA, Sanderson CE, Marathe M, et al. What factors might have led to the emergence of Ebola in West Africa? PLoS Negl Trop Dis. 2015 Jun;9(6):e0003652.
   PubMed Web of Science ®Google Scholar
• Towner JS, Sealy TK, Khristova ML, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 2008 Nov;4(11):e1000212.
   PubMed Web of Science ®Google Scholar
• Mire CE, Geisbert JB, Versteeg KM, et al. A single-vector, single-injection trivalent filovirus vaccine: proof of concept study in outbred Guinea Pigs. J Infect Dis. 2015 [Oct 1];212 Suppl 2:S384–8.
   PubMed Web of Science ®Google Scholar
• Rougeron V, Feldmann H, Grard G, et al. Ebola and Marburg haemorrhagic fever. J Clin Virol. 2015 Mar;64:111–119.
   PubMed Web of Science ®Google Scholar
• De La Vega M-A, Wong G, Kobinger GP, et al. The multiple roles of sGP in Ebola pathogenesis. Viral Immunol. 2015 Feb;28(1):3–9.
   PubMed Web of Science ®Google Scholar
• Wilson JA, Hevey M, Bakken R, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000 [Mar 3];287(5458):1664–1666.
   PubMed Web of Science ®Google Scholar
• Althaus CL, Low N, Musa EO, et al. Ebola virus disease outbreak in Nigeria: transmission dynamics and rapid control. Epidemics. 2015 Jun;11:80–84.
   PubMed Web of Science ®Google Scholar
• Cenciarelli O, Gabbarini V, Pietropaoli S, et al. Viral bioterrorism: learning the lesson of Ebola virus in West Africa 2013-2015. Virus Res. 2015 [Dec 2];210:318–326.
   PubMed Web of Science ®Google Scholar
• Wong G, Kobinger GP. Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak. Clin Microbiol Rev. 2015 Jul;28(3):593–601.
   PubMed Web of Science ®Google Scholar
• Sridhar S. Clinical development of Ebola vaccines. Ther Advances Vaccines. 2015 Sep;3(5–6):125–138.
   PubMedGoogle Scholar
• Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016 Jan;16(1):31–42.
   PubMed Web of Science ®Google Scholar
• De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016 Mar;16(3):311–320.
   PubMed Web of Science ®Google Scholar
• Kennedy SB, Neaton JD, Lane HC, et al. Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: design, procedures, and challenges. Clin Trials. 2016 Feb;13(1):49–56.
   PubMed Web of Science ®Google Scholar
• Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11(7):786–790.
   PubMed Web of Science ®Google Scholar
• Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004;78(10):5458–5465.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015 [Aug 29];386(9996):857–866.
   PubMed Web of Science ®Google Scholar
• Mire CE, Miller AD, Carville A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012;6(3):e1567.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008 Nov;4(11):e1000225.
   PubMed Web of Science ®Google Scholar
• Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med. 2012 [Oct 31];4(158):158ra46.
   Web of Science ®Google Scholar
• Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20(10):1126–1129.
   PubMed Web of Science ®Google Scholar
• Shoemaker T, MacNeil A, Balinandi S, et al. Reemerging Sudan Ebola virus disease in Uganda, 2011. Emerg Infect Dis. 2012 Sep;18(9):1480–1483.
   PubMed Web of Science ®Google Scholar
• Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006 Nov;13(11):1267–1277.
   PubMed Web of Science ®Google Scholar
• Sarwar UN, Costner P, Enama ME, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015 [Feb 15];211(4):549–557.
   PubMed Web of Science ®Google Scholar
• Kibuuka H, Berkowitz NM, Millard M, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet. 2015 [Apr 18];385(9977):1545–1554.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010 [Dec 16];29(2):304–313.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine - preliminary report. N Engl J Med. 2014 [Nov 26].
   PubMed Web of Science ®Google Scholar
• Warfield KL, Dye JM, Wells JB, et al. Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles. Plos One. 2015;10(3):e0118881.
   Web of Science ®Google Scholar
• Zahn R, Gillisen G, Roos A, et al. Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. Plos One. 2012;7(12):e44115.
   PubMed Web of Science ®Google Scholar
• Wang D, Raja NU, Trubey CM, et al. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J Virol. 2006 Mar;80(6):2738–2746.
   PubMed Web of Science ®Google Scholar
• Pratt WD, Wang D, Nichols DK, et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clinical Vaccine Immunology: CVI. 2010 Apr;17(4):572–581.
   PubMed Web of Science ®Google Scholar
• Richardson JS, Pillet S, Bello AJ, et al. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol. 2013 Apr;87(7):3668–3677.
   PubMed Web of Science ®Google Scholar
• Willet M, Kurup D, Papaneri A, et al. Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses. J Infect Dis. 2015 [Oct 1];212 Suppl 2:S414–24.
   PubMed Web of Science ®Google Scholar
• Herbert AS, Kuehne AI, Barth JF, et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol. 2013 May;87(9):4952–4964.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009;83(14):7296–7304.
   PubMed Web of Science ®Google Scholar
• Wong G, He S, Wei H, et al. Development and characterization of a Guinea pig-adapted Sudan virus. J Virol. 2015;90(1):392–399.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-DiCaprio KM, Williams KJ, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol. 2008 Jun;82(11):5664–5668.
   PubMed Web of Science ®Google Scholar
• Wamala JF, Lukwago L, Malimbo M, et al. Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007-2008. Emerg Infect Dis. 2010 Jul;16(7):1087–1092.
   PubMed Web of Science ®Google Scholar
• Kratz T, Roddy P, Tshomba Oloma A, et al. Ebola virus disease outbreak in Isiro, democratic republic of the Congo, 2012: signs and symptoms, management and outcomes. Plos One. 2015;10(6):e0129333.
   PubMed Web of Science ®Google Scholar
• Roddy P, Howard N, Van Kerkhove MD, et al. Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007-2008. Plos One. 2012;7(12):e52986.
   PubMed Web of Science ®Google Scholar
• Falzarano D, Feldmann F, Grolla A, et al. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis. 2011 Nov;204 Suppl 3:S1082–9.
   PubMed Web of Science ®Google Scholar
• Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog. 2010 May;6(5):e1000904.
   PubMed Web of Science ®Google Scholar
• Mire CE, Geisbert JB, Marzi A, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl Trop Dis. 2013;7(12):e2600.
   PubMed Web of Science ®Google Scholar
• Jayme SI, Field HE, De Jong C, et al. Molecular evidence of Ebola Reston virus infection in Philippine bats. Virol J. 2015;12:107.
   PubMed Web of Science ®Google Scholar
• Sayama Y, Demetria C, Saito M, et al. A seroepidemiologic study of Reston ebolavirus in swine in the Philippines. BMC Vet Res. 2012;8:82.
   PubMed Web of Science ®Google Scholar
• Taniguchi S, Sayama Y, Nagata N, et al. Analysis of the humoral immune responses among cynomolgus macaque naturally infected with Reston virus during the 1996 outbreak in the Philippines. BMC Vet Res. 2012;8:189.
   PubMed Web of Science ®Google Scholar
• Jahrling PB, Geisbert TW, Jaax NK, et al. Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic. Archives of Virology Supplementum. 1996;11:115–134.
   PubMedGoogle Scholar
• Miranda ME, Ksiazek TG, Retuya TJ, et al. Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996. Journal of Infectious Diseases. 1999;179 Suppl 1:S115–9.
   PubMed Web of Science ®Google Scholar
• Barrette RW, Metwally SA, Rowland JM, et al. Discovery of swine as a host for the Reston ebolavirus. Science. 2009 [Jul 10];325(5937):204–206.
   PubMed Web of Science ®Google Scholar
• Marsh GA, Haining J, Robinson R, et al. Ebola Reston virus infection of pigs: clinical significance and transmission potential. J Infect Dis. 2011;204 Suppl 3:S804–9.
   PubMed Web of Science ®Google Scholar
• Le Guenno B, Formenty P, Wyers M, et al. Isolation and partial characterisation of a new strain of Ebola virus. Lancet. 1995 [May 20];345(8960):1271–1274.
   PubMed Web of Science ®Google Scholar
• Leroy EM, Telfer P, Kumulungui B, et al. A serological survey of Ebola virus infection in central African nonhuman primates. J Infect Dis. 2004 [Dec 1];190(11):1895–1899.
   PubMed Web of Science ®Google Scholar
• Formenty P, Boesch C, Wyers M, et al. Ebola virus outbreak among wild chimpanzees living in a rain forest of Cote d’Ivoire. J Infect Dis. 1999;179 Suppl 1:S120–6.
   PubMed Web of Science ®Google Scholar
• Lai L, Davey R, Beck A, et al. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. Jama. 2015 [Mar 24-31];313(12):1249–1255.
   PubMed Web of Science ®Google Scholar
• Wong G, Audet J, Fernando L, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine. 2014 [Sep 29];32(43):5722–5729.
   PubMed Web of Science ®Google Scholar
• Mire CE, Geisbert JB, Agans KN, et al. Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. Plos One. 2014;9(4):e94355.
   PubMed Web of Science ®Google Scholar